Background: The genetic mutation in Huntington’s disease (HD) is a CAG repeat expansion in the coding region of the huntingtin (Htt) gene. RNAi strategies have proven effective in substantially down-regulating Htt mRNA in the striatum through delivery of siRNAs or viral vectors based on whole tissue assays, but the extent of htt mRNA lowering in individual neurons is unknown.
Objective: Here we characterize the effect of an AAV9-GFP-miRHtt vector on Htt mRNA levels in striatal neurons of Q140/Q140 knock-in mice.
Methods: HD mice received bilateral striatal injections of AAV9-GFP-miRHtt or AAV9-GFP at 6 or 12 weeks and striata were evaluated at 6 months of age for levels of Htt mRNA and protein and for mRNA signal within striatal neurons using RNAscope multiplex fluorescence in situ hybridization.
Results: Compared to controls, the striatum of 6-month old mice treated at 6 or 12 weeks of age with AAV9-GFP-miRHtt showed a reduction of 40–50% in Htt mRNA and lowering of 25–40% in protein levels. The number of Htt mRNA foci in medium spiny neurons (MSNs) of untreated Q140/Q140 mice varied widely per cell (0 to 34 per cell), with ∼10% of MSNs devoid of foci. AAV9-GFP-miRHtt treatment shifted the distribution toward lower numbers and the percentage of cells without foci increased to 14–20%. The average number of Htt mRNA foci per MSN was reduced by 43%.
Conclusions: The findings here show that intrastriatal infusion of an AAV9-GFP-miRHtt vector lowers mRNA expression of Htt in striatum by ∼50%, through a partial reduction in the number of copies of mutant Htt mRNAs per cell. These findings demonstrate at the neuronal level the variable levels of Htt mRNA expression in MSNs and the neuronal heterogeneity of RNAi dependent Htt mRNA knockdown.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Grou. Cell. 1993;72(6):971–83.
2.
DiFigliaM, SappE, ChaseKO, DaviesSW, BatesGP, VonsattelJP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science1997;277(5334):1990–3.
3.
AroninN, DiFigliaM. Huntingtin-lowering strategies in Huntington’s disease: Antisense oligonucleotides, small RNAs, and gene editing. Mov Disord. 2014;29(11):1455–61.
4.
MiyazakiY, AdachiH, KatsunoM, MinamiyamaM, JiangYM, HuangZ, et al. Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med. 2012;18(7):1136–41.
5.
KotaJ, ChivukulaRR, O’DonnellKA, WentzelEA, MontgomeryCL, HwangHW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–17.
6.
StoicaL, TodeasaSH, CabreraGT, SalamehJS, ElMallahMK, MuellerC, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79(4):687–700.
7.
XiaH, MaoQ, EliasonSL, HarperSQ, MartinsIH, OrrHT, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10(8):816–20.
8.
HarperSQ, StaberPD, HeX, EliasonSL, MartinsIH, MaoQ, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A.. 2005;102(16):5820–5.
9.
McBrideJL, BoudreauRL, HarperSQ, StaberPD, MonteysAM, MartinsI, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105(15):5868–73
.
10.
StanekLM, SardiSP, MastisB, RichardsAR, TreleavenCM, TaksirT, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–74.
11.
DufourBD, SmithCA, ClarkRL, WalkerTR, McBrideJL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington’s disease mice. Mol Ther. 2014;22(4):797–810.
12.
MenalledLB, SisonJD, DragatsisI, ZeitlinS, ChesseletMF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11–26.
13.
HickeyMA, KosmalskaA, EnayatiJ, CohenR, ZeitlinS, LevineMS, et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington’s disease mice. Neuroscience. 2008;157(1):280–95.
14.
ValenciaA, SappE, KimmJS, McCloryH, AnsongKA, YohrlingG, et al. Striatal synaptosomes from Hdh140Q/140Q knock-in mice have altered protein levels, novel sites of methionine oxidation, and excess glutamate release after stimulation. J Huntingtons Dis. 2013;2(4):459–75.
15.
FranichNR, FitzsimonsHL, FongDM, KlugmannM, DuringMJ, YoungD. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther. 2008;16(5):947–56.
16.
BoudreauRL, McBrideJL, MartinsI, ShenS, XingY, CarterBJ, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009;17(6):1053–63.
17.
MuellerC, TangQ, GruntmanA, BlomenkampK, TeckmanJ, SongL, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther. 2012;20(3):590–600.
18.
GaoG, AlviraMR, SomanathanS, LuY, VandenbergheLH, RuxJJ, et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A. 2003;100(10):6081–6.
19.
DiFigliaM, SappE, ChaseK, SchwarzC, MeloniA, YoungC, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 1995;14(5):1075–81.
20.
WangG,
LiuX,
GaertigMA,
LiS,
LiXJ. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016;113(12):3359–64.
21.
DueckH, KhaladkarM, KimTK, SpaethlingJM, FrancisC, SureshS, et al. Deep sequencing reveals cell-type-specific patterns of single-cell transcriptome variation. Genome Biol. 2015;16:122.
22.
WangN, GrayM, LuXH, CantleJP, HolleySM, GreinerE, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat Med. 2014;20(5):536–41.
23.
CearleyCN, WolfeJH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther.. 2006;13(3):528–37.
24.
CearleyCN, WolfeJH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci. 2007;27(37):9928–40.
25.
SalegioEA, SamaranchL, KellsAP, MittermeyerG, San SebastianW, ZhouS, et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 2013;20(3):348–52.
26.
San SebastianW, SamaranchL, HellerG, KellsAP, BringasJ, PivirottoP, et al. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther. 2013;20(12):1178–83.
27.
HadaczekP, StanekL, CiesielskaA, SudhakarV, SamaranchL, PivirottoP, et al. Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: Implications for Huntington’s disease. Mol Ther Methods Clin Dev. 2016;3:16037.
